Recent Clinical Trials by Gilead Sciences are evaluating MMP activity in different solid tumors, including non-small cell lung carcinoma (NSCLC), pancreatic adenocarcinoma, colorectal cancer (CRC) and breast cancer, and their effect in the tumor microenvironment by using an anti-MMP-9 therapeutic antibody [18]. The gene discussed is MMP9; the disease is breast carcinoma.